Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Free by publisher |
as soon as is submitted to ZB.
SURMOUNTing body weight barriers in type 2 diabetes.
Med. 4, 849-851 (2023)
The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues set out to examine the weight loss efficacy of the GIPR:GLP-1R co-agonist tirzepatide in patients with obesity and type 2 diabetes, reporting that tirzepatide has unprecedented efficacy in a magnitude historically considered almost unattainable.1.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Editorial
Keywords
Obesity
ISSN (print) / ISBN
2666-6359
e-ISSN
2666-6340
Journal
Med (N Y)
Quellenangaben
Volume: 4,
Issue: 12,
Pages: 849-851
Publisher
Cell Press
Publishing Place
50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)
Grants
German Center for Diabetes Research (DZD e.V.)
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted